| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
LY2228820 manufacturers
- Ralimetinib
-
-
2026-07-27
- CAS:862505-00-8
- Purity: 99.16%
- Supply Ability: 10g
|
| | LY2228820 Basic information |
| Product Name: | LY2228820 | | Synonyms: | RALIMETINIB (LY2228820);5-[2-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine;7-(2-tert-Butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine;Ralimetinib dimesylate;7-(2-tert-Butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-am;3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-;3H-Imidazo[4,5-b]pyridin-2-amine,5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)- | | CAS: | 862505-00-8 | | MF: | C24H29FN6 | | MW: | 420.53 | | EINECS: | | | Product Categories: | | | Mol File: | 862505-00-8.mol |  |
| | LY2228820 Chemical Properties |
| | LY2228820 Usage And Synthesis |
| Uses | Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1]. | | IC 50 | p38β MAPK: 3.2 nM (IC50); p38α MAPK: 5.3 nM (IC50) | | References | [1] Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74. DOI:10.1158/1535-7163.MCT-13-0513 |
| | LY2228820 Preparation Products And Raw materials |
|